Trial · NCT03148691

A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis

NCT03148691, Phase 2, Completed, Aclaris Therapeutics, Inc.; results first posted 2019-05-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis. Trials, record NCT03148691. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03148691

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis
NCT number: NCT03148691
Status: Completed
Phases: Phase 2
Enrollment: 253 participants, actual
Lead sponsor: Aclaris Therapeutics, Inc.
Conditions: Seborrheic Keratosis
Interventions: A-101
First posted: 2017-05-11
Last updated: 2019-05-06
Results first posted: 2019-05-06

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Mean of Per Subject Percentages of Target Lesions Judged to be Clear (PWA=0) at Visit 8	Day 106	Mean of per subject percentages of target lesions judged to be clear (PWA=0) at Visit 8 Grade Descriptor 0 Clear: no visible seborrheic keratosis lesion 1. Near Clear: a visible seborrheic keratosis lesion with a surface appearance different from the surrounding skin (not elevated) 2. Thin: a visible seborrheic keratosis lesion (thickness ≤ 1 mm) 3. Thick: a visible seborrheic keratosis lesion (thickness \> 1 mm)

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Mean of Per Subject Percentages of Target Lesions Judged to be Clear (PWA=0) at Visit 8	Day 106		Per-Subject Percent of Lesions Clear	MEAN

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Mean of Per Subject Percentages of Target Lesions Judged to be Clear (PWA=0) at Visit 8	Vehicle	3.72	Standard Deviation 10.4	Per-Subject Percent of Lesions Clear
Mean of Per Subject Percentages of Target Lesions Judged to be Clear (PWA=0) at Visit 8	A-101 Low Dose	49.5	Standard Deviation 36.74	Per-Subject Percent of Lesions Clear
Mean of Per Subject Percentages of Target Lesions Judged to be Clear (PWA=0) at Visit 8	A-101 High Dose	57.88	Standard Deviation 35.92	Per-Subject Percent of Lesions Clear

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Vehicle	50
Overall Study	STARTED	A-101 Low Dose	103
Overall Study	STARTED	A-101 High Dose	100
Overall Study	COMPLETED	Vehicle	47
Overall Study	COMPLETED	A-101 Low Dose	101
Overall Study	COMPLETED	A-101 High Dose	92
Overall Study	NOT COMPLETED	Vehicle	3
Overall Study	NOT COMPLETED	A-101 Low Dose	2
Overall Study	NOT COMPLETED	A-101 High Dose	8

Source ClinicalTrials.gov

Adverse events201

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Atrial Fibrillation	Cardiac disorders	Vehicle	1	50	1
other	Atrial Fibrillation	Cardiac disorders	A-101 Low Dose	0	103	0
other	Atrial Fibrillation	Cardiac disorders	A-101 High Dose	0	100	0
other	Bundle Branch Block Left	Cardiac disorders	Vehicle	0	50	0
other	Bundle Branch Block Left	Cardiac disorders	A-101 Low Dose	1	103	1
other	Bundle Branch Block Left	Cardiac disorders	A-101 High Dose	0	100	0
other	Tachycardia	Cardiac disorders	Vehicle	1	50	1
other	Tachycardia	Cardiac disorders	A-101 Low Dose	0	103	0
other	Tachycardia	Cardiac disorders	A-101 High Dose	0	100	0
other	Eyelid Oedema	Eye disorders	Vehicle	0	50	0

1 to 10 of 201Source ClinicalTrials.gov

See all 201 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Vehicle	0	50
Total, all-cause mortality	A-101 Low Dose	0	103
Total, all-cause mortality	A-101 High Dose	0	100
Total, other adverse events	Vehicle	11	50
Total, other adverse events	A-101 Low Dose	18	103
Total, other adverse events	A-101 High Dose	26	100
Total, serious adverse events	Vehicle	1	50
Total, serious adverse events	A-101 Low Dose	2	103
Total, serious adverse events	A-101 High Dose	1	100

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03148691

GET https://conductscience.org/api/trials/v1/NCT03148691/events?page=2

API reference For AI assistants